证券日报网讯 2月5日，德源药业发布2025年年度业绩快报公告称，公司2025年实现营业收入1，057， 759，831.41元，同比增长21.80%；归属于上市公司股东的净利润为236，929，075.58元，同比增长 33.87%。 （文章来源：证券日报） ...

北京商报讯（记者 丁宁）2月5日晚间，德源药业（920735）发布2025年年度业绩快报显示，2025年实 现营业收入10.58亿元，同比增长21.8%；对应实现的归属净利润约为2.37亿元，同比增长33.87%。 德源药业表示，2025年，面对激烈严峻的市场竞争环境、医药行业政策密集调整以及集采降价等因素的 影响，公司主动应对环境变化，通过努力扩大市场份额、优化产品销售结构、协同推进仿制药与创新药 管线发展及精细化成本管控等举措，实现了整体经营业绩的稳健增长。 ...

德源药业发布业绩快报，2025年度实现营业收入10.58亿元，同比增长21.80%；净利润2.37亿元，同比 增长33.87%。报告期内，公司经营业绩增长的主要原因是：公司始终坚持营销为先的经营理念，持续 夯实销售基础，全力推进市场开拓，实现在售产品销量稳健增长。其中，"复瑞彤"和"波开清"销量保持 稳步攀升，为公司销售收入增长奠定良好的基础；卡格列净片、恩格列净片、二甲双胍恩格列净片 （III）等产品销售规模较快增长，依折麦布片、非布司他片等新获批品种的上市销售，进一步推动经营 业绩稳步提升；利格列汀片（5mg）、西格列汀二甲双胍片（Ⅱ）（50mg/850mg）、磷酸西格列汀片 （100mg）等产品中标第十批药品集中带量采购，自2025年3月起发货至相关中标区域，推动销售规模 较快增长；公司持续强化内部运营管理，优化人员结构，严格费用管控，降本增效，全面提升整体盈利 水平与经营质量。 ...

证券日报网讯 12月10日晚间，德源药业发布公告称，2025年12月9日，江苏德源药业股份有限公司按照 化学药品3类申报的别嘌醇片收到国家药品监督管理局（NMPA）核准签发的药品注册证书，且视同通 过一致性评价。 （文章来源：证券日报） ...

Market Overview - The chemical pharmaceutical sector experienced a decline of 1.44% on November 19, with Hainan Haiyao leading the drop [1] - The Shanghai Composite Index closed at 3946.74, up 0.18%, while the Shenzhen Component Index closed at 13080.09, unchanged [1] Stock Performance - Notable gainers in the chemical pharmaceutical sector included: - Shanhe Pharmaceutical (300452) with a closing price of 15.07, up 9.04% and a trading volume of 390,200 shares, totaling 586 million yuan [1] - ST Suhao (600200) closed at 1.02, up 5.15% with a trading volume of 429,200 shares [1] - ST Jingfeng (000908) closed at 66.8, up 5.02% with a trading volume of 354,800 shares [1] - Major decliners included: - Muan Nanhai (000566) with a closing price of 7.20, down 10.00% and a trading volume of 2,192,500 shares, totaling 1.625 billion yuan [2] - Sitaili (603520) closed at 10.66, down 6.74% with a trading volume of 315,600 shares [2] - Yatai Pharmaceutical (002370) closed at 7.79, down 6.59% with a trading volume of 1,044,700 shares [2] Capital Flow - The chemical pharmaceutical sector saw a net outflow of 2.278 billion yuan from institutional investors, while retail investors contributed a net inflow of 2.139 billion yuan [2] - The top stocks by net inflow from institutional investors included: - Changshan Pharmaceutical (300255) with a net inflow of 71.90 million yuan, accounting for 6.20% of total inflow [3] - Xingqi Eye Medicine (300573) with a net inflow of 70.33 million yuan, representing 12.29% [3] - Shanhe Pharmaceutical (300452) with a net inflow of 68.13 million yuan, making up 11.62% [3]

Group 1 - The event "Investor Zero Distance" focused on the company Deyuan Pharmaceutical, part of the North Exchange 50 index, highlighting its innovative growth in the pharmaceutical industry [2][7] - Over 40 institutional representatives and investors participated in the event, engaging with company executives to understand the company's operations and market potential [2][6] - Deyuan Pharmaceutical specializes in the research, production, and sales of chronic disease treatment drugs, particularly in the endocrine therapy sector, and is expanding its product pipeline in related fields [4][6] Group 2 - The company's chairman and board secretary provided insights into the current business operations, strategic direction, and core technologies during face-to-face discussions with investors [6] - Industry experts discussed the North Exchange market, the North Exchange 50 index fund, and the long-term investment value of the A-share pharmaceutical sector during a subsequent seminar [6] - The event aimed to enhance communication between investors and listed companies, fostering a better understanding of company fundamentals and promoting rational investment culture [7]

Group 1 - The core viewpoint of the articles highlights a significant surge in the innovative drug sector within the A-share market, particularly on October 31, where several stocks, including Shuyat and Sanofi, hit the 20% daily limit increase [1] - The A-share market experienced fluctuations, with the ChiNext index dropping over 2%, and the total trading volume in the Shanghai and Shenzhen markets reaching 2.32 trillion yuan, a decrease of 103.9 billion yuan compared to the previous trading day [1] - The introduction of the "Commercial Insurance Innovative Drug Directory" mechanism during the national medical insurance negotiations is expected to benefit innovative drugs that are highly innovative and clinically valuable but are not yet included in the basic directory [1] Group 2 - According to Guosen Securities, the Chinese innovative drug industry is showing a long-term positive development trend, particularly evident in the explosive growth of BD transactions in recent years [2] - For most domestic innovative drugs, external licensing is often just the starting point for global development, with the progress of partners overseas and subsequent global clinical data readings enhancing the certainty of commercialization in the global market [2] - The long-term logic of investing in innovative drugs is favored, with a focus on stocks that are showing signs of bottom reversal [2]

Core Viewpoint - The innovation drug sector is experiencing significant market activity, driven by supportive government policies aimed at promoting the development of innovative drugs and medical devices in China [1] Group 1: Market Performance - Companies such as Sanofi, Sihuan Pharmaceutical, and Zai Lab have seen stock price increases of 20% or more, indicating strong investor interest in the innovation drug sector [1] - Other companies like Maiwei Biotech and Deyuan Pharmaceutical have also reported stock price increases exceeding 10% [1] Group 2: Policy Support - The "14th Five-Year Plan" suggests support for the development of innovative drugs and medical devices, with a focus on four key areas: R&D support, commercial health insurance innovation drug catalog, optimization of drug pricing mechanisms, and support for the application of innovative drugs and devices [1] - The Chinese government has reiterated its commitment to supporting the innovation drug sector starting in 2025, indicating a long-term strategy for growth [1] Group 3: Industry Challenges and Solutions - According to CITIC Securities, the current bottlenecks in the domestic innovation drug development are primarily in the payment and application sectors [1] - The development of commercial health insurance is deemed essential, with the establishment of a commercial insurance catalog playing a guiding role in market pricing for innovative drugs [1] - Strategies such as DRG/DIP exclusion payment, accelerated hospital promotion, and diversified payment methods are identified as key measures for the domestic development of innovative drugs [1]

Core Points - The Shanghai Composite Index closed at 3961.62 points, above the six-month moving average, with a decline of 0.63% [1] - The total trading volume of A-shares reached 157.92 billion yuan [1] - A total of 259 A-shares have surpassed the six-month moving average, with notable stocks showing significant deviation rates [1] Summary by Category Market Performance - The Shanghai Composite Index is currently at 3961.62 points, indicating a slight decline of 0.63% [1] - The total trading volume for A-shares today is reported at 157.91 billion yuan [1] Stocks Surpassing Six-Month Moving Average - 259 A-shares have broken through the six-month moving average, with the highest deviation rates observed in stocks such as: - Yatong Precision Engineering (8.20%) - Excellent New Energy (7.57%) - Deyuan Pharmaceutical (7.38%) [1] - Other stocks with smaller deviation rates include: - New Hope - Shanghai Phoenix - Angli Education, which have just crossed the six-month line [1] Notable Stocks and Their Metrics - Top stocks with significant price changes and their metrics include: - Yatong Precision Engineering: +9.76%, turnover rate 31.45%, six-month line 23.27 yuan, latest price 25.18 yuan, deviation rate 8.20% [1] - Excellent New Energy: +9.90%, turnover rate 2.44%, six-month line 45.62 yuan, latest price 49.07 yuan, deviation rate 7.57% [1] - Deyuan Pharmaceutical: +11.83%, turnover rate 8.02%, six-month line 38.03 yuan, latest price 40.84 yuan, deviation rate 7.38% [1]

国浩律师（南京）事务所 关 于 江苏德源药业股份有限公司 2025 年第一次临时股东会 之 法律意见书 国浩律师(南京)事务所 法律意见书 国浩律师（南京）事务所 南京市汉中门大街 309 号 B 座 5/7/8 层 邮编：210036 5,7,8th Floor, Block B, 309 Hanzhongmen Street, Nanjing 210036, China 电话/Tel: +86 25 8966 0900 传真/Fax: +86 25 8966 0966 网址/Website: http://www.grandall.com.cn 2025 年 9 月 | 一、 | 关于本次临时股东会的召集、召开程序 2 | | --- | --- | | 二、 | 关于本次临时股东会出席人员的资格和召集人资格 3 | | 三、 | 关于本次临时股东会的表决程序及表决结果 4 | | 四、 | 结论意见 7 | | | 签署页 9 | 关于江苏德源药业股份有限公司 2025年第一次临时股东会之法律意见书 致：江苏德源药业股份有限公司 根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华人民共和 国 ...